

China's CK Life Sciences establishes Sequencio Therapeutics for cancer vaccines development

March 12, 2026 | News

Development of therapeutic cancer vaccines designed to train a patient's own immune system



Hong Kong-based CK Life Sciences has announced the establishment of Sequencio Therapeutics, a wholly-owned subsidiary dedicated to advancing the company's therapeutic cancer vaccine portfolio.

Sequencio Therapeutics has been established to consolidate CK Life Sciences' therapeutic cancer vaccine research and development portfolio under a dedicated organisation, reflecting the company's strategic focus on this emerging class of cancer immunotherapy. The subsidiary is focused on the development of therapeutic cancer vaccines designed to train a patient's own immune system to achieve durable, long-term remission with a favourable safety profile, addressing key limitations of current standard-of-care therapies.

The establishment of Sequencio supports a long-term vision of shifting cancer treatment paradigms from transient tumour reduction toward sustained, immune-controlled remission, with vaccine discovery and design conducted in-house and development advanced through a combination of internal capabilities and external collaborations.

Sequencio's preclinical portfolio includes the company's investigational cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (TROP2), which has demonstrated robust T-cell immune responses and achieved 100% tumour growth inhibition in preclinical breast and colorectal cancer mouse studies. The portfolio also includes vaccine candidates targeting PRAME (Preferentially Expressed Antigen in Melanoma), PD-L1 (programmed cell death ligand 1), B7-H3 (B7 homolog 3), and Claudin 6.

Over the past two years, CK Life Sciences has undergone a comprehensive restructuring to maximise the potential of its R&D portfolio, with a view to attracting additional funding from investors. In 2025, the company's late-stage melanoma vaccine seviprotimut-L was sold to Nasdaq-listed TransCode in exchange for an equity stake in Transcode. Through the integration of seviprotimut-L into TransCode Therapeutics' pipeline, the potential synergy between vaccine-driven immunity and RNA-based mechanisms presents an opportunity to explore new approaches to addressing treatment resistance and achieving more durable patient responses.